Chronic Hepatitis C
Conditions
Brief summary
The purpose fo the study is to evaluate the efficacy defined by the sustained virological response (SVR), in patients with compensated cirrhosis treated with PEG-IFN, RBV and telaprevir or boceprevir in the French Early Access Program for the use of protease inhibitors or after the approval of these drugs through the the marketing authorization.
Detailed description
Methodology: Multicentric French national cohort with prospective collection of data and constitution of biobank, in HCV genotype 1 patients with compensated cirrhosis who failed to eradicate HCV with the combination PEG-IFN and RBV, treated with protease inhibitor (telaprevir or boceprevir), PEG-IFN and RBV, included in the French Early Access Program for the use of protease inhibitors or after approval of these drugs through the the marketing authorization. Primary objective: Evaluate the efficacy defined by the sustained virological response (SVR), in patients with compensated cirrhosis treated with PEG-IFN, RBV and telaprevir or boceprevir in the French Early Access Program for the use of protease inhibitors or after the approval of these drugs. Estimated enrollment: 900 patients treated in the French Early Access Program for the use of protease inhibitors and after the marketing authorization approval. Treatments: * with telaprevir: triple combination with PEG-IFN alfa-2a, 180 µg/week, ribavirin 1000 to 1200 mg/d according the body weight and telaprevir 750 mg/8h, for 12 weeks followed by PEG-IFN and RBV for 36 weeks for a total duration of treatment of 48 weeks. * or with boceprevir: triple combination with PEG-IFN alfa-2b, 1,5 µg/kg/week, RBV 800 to 1400 mg/d according the body weight and boceprevir 800 mg/8h. The treatment will begin after a lead in phase of PEG-IFN and RBV for 4 weeks, followed by a triple combination (PEG-IFN, RBV and boceprevir)during 44 weeks for a total duration of treatment of 48 weeks. Estimated planning: * study start date: February 2011 * enrollment period: 14 months * subject participation duration: 12 months of treatment and 12 months of follow-up = 24 months * total study duration: 38 months. The last visit of the last enrolled patient is prevised in February 2014, the end of analysis on biobank in May 2014 (long term follow up of resistant mutants). Some blood samples will be preserved for scientific future research. Study design: national French multicentric cohort in patients with HCV-related cirrhosis treated in the French Early Access Program for the use of boceprevir or telaprevir or after the marketing authorization approval of these drugs associated with PEG-IFN and RBV with a collection of clinical and biological data and constitution of a biobank.
Interventions
None listed
Sponsors
ANRS, Emerging Infectious Diseases
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients who need the criteria of French Early Access Program for boceprevir and telaprevir or after the marketing authorization approval: * patients aged of 18 years or more with chronic hepatitis C * relapsers or partial-responders or null-responders to treatment with PEG'IFN α2a or 2b associated or not with RBV * chronic infection with genotype 1 HCV * fibrosis Metavir score of 4 (cirrhosis) * without decompensated liver disease * naïve of direct anti-viral treatment * without HIV or HBV co-infection * signature of participation to the cohort
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of sustained virological response (SVR) defined by an undetectable RNA by real-time PCR. | 6 months after discontinuation of therapy (at week 72) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Virological response during and after the treatment with determination of HCV RNA levels as prevised by the French Early Access Program for the use of protease inhibitors and after the approval. | at D0, W4, W8, W12, W24, W48 and 12 (W60) and 24 (W72) weeks after the discontinuation of treatment | This will allow to define: * rate of non response (detectable RNA during the treatment) * rate of virological breakthrough (undetectable HCV RNA then detectable during the treatment) * rate of virological relapse after the discontinuation of treatment (undetectable HCV RNA at the end of therapy then detectable after the treatment) |
| early viral kinetic | at the D0, W1, W2 and W4 | — |
| Rate of premature discontinuation of protease inhibitor, RBV and/or PEG-IFN | in may 2014 (3 month after study completion date) | — |
| occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank) | in may 2014 (3 month after study completion date) | — |
| Evolution of quality of life scores | in may 2014 (3 month after study completion date) | — |
| Evaluation of therapeutic observance with auto-questionnaires | in may 2014 (3 month after study completion date) | — |
| Rate of adaptation of dosage of protease inhibitors, RBV and/or PEG-IFN | in may 2014 (3 month after study completion date) | — |
Countries
France
Outcome results
None listed